---
title: "Walvax Biotechnology Co.,Ltd. (300142.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300142.SZ.md"
symbol: "300142.SZ"
name: "Walvax Biotechnology Co.,Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T23:48:16.062Z"
locales:
  - [en](https://longbridge.com/en/quote/300142.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300142.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300142.SZ.md)
---

# Walvax Biotechnology Co.,Ltd. (300142.SZ)

## Company Overview

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.walvax.com](https://www.walvax.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.59% |  |
| Net Profit YoY | 118.68% |  |
| P/B Ratio | 3.06 |  |
| Dividend Ratio | 0.28% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 22735123084.06 |  |
| Revenue | 2404094175.01 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.39% | C |
| Profit Margin | 11.91% | B |
| Gross Margin | 68.47% | A |
| Revenue YoY | -10.59% | E |
| Net Profit YoY | 118.68% | A |
| Total Assets YoY | -22.53% | E |
| Net Assets YoY | -31.99% | E |
| Cash Flow Margin | 221.28% | B |
| OCF YoY | -10.59% | E |
| Turnover | 0.19 | D |
| Gearing Ratio | 29.79% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Walvax Biotechnology Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.59%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "118.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.06",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.28%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "22735123084.06",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2404094175.01",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.39%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "11.91%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "68.47%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-10.59%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "118.68%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-22.53%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-31.99%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "221.28%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-10.59%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "29.79%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 78.46 | 29/81 | 416.36 | 371.22 | 128.51 |
| PB | 3.03 | 46/81 | 2.21 | 2.01 | 1.88 |
| PS (TTM) | 9.34 | 45/81 | 8.26 | 7.82 | 7.20 |
| Dividend Yield | 0.29% | 35/81 | 0.32% | 0.09% | 0.08% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-29T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Sell | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.02 |
| Highest Target | 8.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300142.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300142.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300142.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300142.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**